BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

By T. King, K. Brown, G. Raghu, R. D. du Bois, D. Lynch, F. Martinez, D. Valeyre, I. Leconte, A. Morganti, S. Roux and 1 more. American Journal of Respiratory and Critical Care Medicine, 2011

659 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/baa6f9a495bf2efeb4f8a06e01c30ff0e1231533

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. H. Collard
2. G. Raghu

Citations in the corpus

• An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. (2015, background): “Two RCTs examined the effect of bosentan versus placebo (49, 50), whereas a single RCT tested macitentan versus placebo (51).”